Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 7:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 403 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: intranasal placebo Clear all
Not listed Phase 2Phase 3 Interventional

Emergency Ketamine Treatment of Suicidal Ideation

NCT02183272
View directory record Official record
Conditions
Depression, Suicidal Ideation, Suicidal Impulses
Interventions
Intranasal Ketamine, Intranasal Saline Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Sep 23, 2026, 7:23 AM EDT
Completed Phase 3 Interventional Results available

Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)

NCT00289198
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
FF, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
8
States / cities
San Diego, California • Baltimore, Maryland • Wheaton, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Sep 23, 2026, 7:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy Study of Intranasal Insulin to Treat Tobacco Abstinence Syndrome

NCT01781234
View directory record Official record
Conditions
Tobacco Abstinence Syndrome
Interventions
Intranasal Insulin, Placebo
Drug
Lead sponsor
Ajna Hamidovic
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 9, 2018 · Synced Sep 23, 2026, 7:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Intranasal Oxytocin and Enhancement of Team Cohesion

NCT02302430
View directory record Official record
Conditions
Unit Cohesion
Interventions
Oxytocin, Placebo comparator
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 28 Years
Enrollment
486 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2019 · Synced Sep 23, 2026, 7:23 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958
View directory record Official record
Conditions
Treatment Resistant Depressive Disorder
Interventions
Esketamine 14 mg, Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
20 Years to 64 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
14
States / cities
Birmingham, Alabama • Garden Grove, California • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 23, 2026, 7:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nebulizer Delivery of Intranasal Scopolamine

NCT04999449
View directory record Official record
Conditions
Scopolamine, Motion Sickness
Interventions
Scopolamine, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
21 Years to 49 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Sep 23, 2026, 7:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Reinforcing Effects of Cocaine During Phendimetrazine Maintenance

NCT02522325
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Phendimetrazine, Cocaine, Placebo
Drug
Lead sponsor
William Stoops
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 23, 2026, 7:23 AM EDT
Completed Phase 2 Interventional Results available

Impact of Oxytocin on Obstructive Sleep Apnea Induced Changes in Sleep

NCT03148899
View directory record Official record
Conditions
Sleep Apnea, Obstructive
Interventions
Oxytocin Intranasal Spray, Placebo Intranasal Spray
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Sep 23, 2026, 7:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children

NCT04444284
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Investigational RSV vaccine MV-012-968 (Dosage 1), Investigational RSV vaccine MV-012-968 (Dosage 2), Placebo, Investigational RSV vaccine MV-012-968 (Dosage 3)
Biological · Other
Lead sponsor
Meissa Vaccines, Inc.
Industry
Eligibility
15 Months to 59 Months
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
Norfolk, Nebraska • Omaha, Nebraska • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Sep 23, 2026, 7:23 AM EDT
Completed Phase 2 Interventional Results available

Intranasal Insulin for Posttraumatic Stress Disorder

NCT04044534
View directory record Official record
Conditions
PTSD
Interventions
Intranasal insulin, Placebo
Drug
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 23, 2026, 7:23 AM EDT
Completed Phase 3 Interventional Results available

Intranasal Ketorolac Versus Intravenous Ketorolac for Treatment of Migraine Headaches in Children

NCT02358681
View directory record Official record
Conditions
Migraine
Interventions
Ketorolac, intranasal, Ketorolac, intravenous, Placebo, intravenous, Placebo, intranasal
Drug
Lead sponsor
Columbia University
Other
Eligibility
8 Years to 17 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Sep 23, 2026, 7:23 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Neural Mechanisms of Immersive Virtual Reality in Chronic Pain

NCT04851301
View directory record Official record
Conditions
Pain, Virtual Reality, Placebo, Temporomandibular Disorder
Interventions
Active Virtual Reality, sham Virtual Reality, No Intervention, Naloxone, Saline, Natural history
Behavioral · Other · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 23, 2026, 7:23 AM EDT
Completed Phase 2 Interventional Results available

Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma

NCT05363670
View directory record Official record
Conditions
Asthma
Interventions
ARS-1 1 mg, Albuterol MDI, Placebo, ARS-1 2mg
Drug
Lead sponsor
ARS Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Tampa, Florida • Chevy Chase, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 23, 2026, 7:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intranasal Fentanyl for Pain Control During First-Trimester Uterine Aspiration

NCT03057041
View directory record Official record
Conditions
Pain Uterus
Interventions
Fentanyl, placebo
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
14 Years and older · Female only
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Honolulu, Hawaii • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Sep 23, 2026, 7:23 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone

NCT01760473
View directory record Official record
Conditions
Heroin Dependence
Interventions
Intranasal challenge drug
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Sep 23, 2026, 7:23 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of IGM-6268 in Healthy Volunteers

NCT05160402
View directory record Official record
Conditions
Healthy Volunteers
Interventions
IGM-6268, Placebo
Drug
Lead sponsor
IGM Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Sep 23, 2026, 7:23 AM EDT
Completed Phase 4 Interventional Results available

Intranasal Midazolam in Children as a Pre-Operative Sedative - Part 2

NCT02356705
View directory record Official record
Conditions
Sedation
Interventions
Midazolam, xylocaine, saline placebo
Drug
Lead sponsor
Jennifer Victory, RN, CCRC
Other
Eligibility
18 Months to 7 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Cooperstown, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Sep 23, 2026, 7:23 AM EDT
Completed Phase 3 Interventional

A Study Of GW685698X For The Treatment Of Perennial Allergic Rhinitis In Pediatrics

NCT00116883
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
GW685698X aqueous nasal spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Years to 11 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
12
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Sep 23, 2026, 7:23 AM EDT
Not listed Phase 1 Interventional

Oxytocin in Opiate Dependence: A Pilot Study of the Effects of Intranasal Oxytocin on Emotional Processes and Stress Responses in Patients With Opiate Dependence

NCT02052258
View directory record Official record
Conditions
Opiate Dependence
Interventions
Oxytocin
Drug
Lead sponsor
MacDonald, Kai, M.D.
Individual
Eligibility
18 Years and older · Male only
Timeline
Started 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2014 · Synced Sep 23, 2026, 7:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose-Finding Study of Intranasal Insulin in Healthy Participants Insulin in Healthy Participants

NCT05062785
View directory record Official record
Conditions
Out-Of-Hospital Cardiac Arrest, Healthy
Interventions
Intranasal insulin
Drug
Lead sponsor
Robert Silbergleit
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 23, 2026, 7:23 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Understanding Cognition, Oxytocin & Pain in Elders

NCT03878589
View directory record Official record
Conditions
Knee Osteoarthritis, Osteoarthritis
Interventions
Oxytocin (OT), Placebo (P)
Drug
Lead sponsor
University of Florida
Other
Eligibility
45 Years to 100 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 23, 2026, 7:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

NCT01859143
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Trivalent Influenza Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
3
States / cities
Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 9, 2014 · Synced Sep 23, 2026, 7:23 AM EDT
Completed Phase 2 Interventional Results available

Intranasal Insulin in Parkinson's Disease

NCT04251585
View directory record Official record
Conditions
Parkinson Disease
Interventions
Regular Novolin R, Placebo
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
41 Years to 89 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 23, 2026, 7:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults

NCT04148118
View directory record Official record
Conditions
Anthrax
Interventions
BW-1010: 50 µg - sprayer - IN, BW-1010: 50 µg - pipette - IN, BW-1010: 100 µg - sprayer - IN, BW-1010: 100 µg - pipette - IN, Saline (Placebo) - sprayer - IN, Saline (Placebo) - pipette - IN, BioThrax (positive control) - SC
Biological
Lead sponsor
BlueWillow Biologics
Industry
Eligibility
18 Years to 49 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Sep 23, 2026, 7:23 AM EDT